Press Releases

VaxInnate Appoints Former CDC Division Chief Thomas Monath to Board of Directors

VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the appointment of Thomas P. Monath, MD to the Company’s board of directors. Dr. Monath is an internationally known virologist and vaccinologist with significant experience in the biotechnology industry and at the Centers for Disease Control and Prevention (CDC).

read more

VaxInnate to Present at Needham & Company 14th Annual Healthcare Conference

VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology, today announced plans to present at the Needham & Company 14th Annual Healthcare Conference. The presentation by Wayne Pisano, VaxInnate’s president and chief executive officer, will take on place Wednesday, April 15, 2015 at 10:00 am at The Westin Grand Central Hotel in New York City, NY.

read more

VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines

Allows for Non-Dilutive Funding of $53 Million. VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology, today announced that it has executed a contract modification with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) to extend the base period of its current contract (HHSO100201100011C) through February 2016.

read more

VaxInnate Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly

Study to assess safety and immunogenicity in high-priority, at-risk population; top-line results expected in second quarter of 2015. VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 1b/2 study of VAX2012Q in healthy adults 65-75 years of age.

read more

VaxInnate Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Meets Phase 1 Seasonal Influenza Endpoints

Top-Line Seroprotection Rates Exceed 90% in each of Four Vaccine Components; VAX2012Q to Proceed into Phase 2 Evaluation in 2015. VaxInnate Corporation, a biotechnology firm pioneering next-generation vaccine technology, announced today that enrollment has concluded in the Phase 1 study of the Company’s experimental recombinant quadrivalent seasonal influenza vaccine, VAX2012Q. Top-line results showed that doses as low as 2 mcg per component were immunogenic, with mean seroprotection rates exceeding 90% for each of the four vaccine components at the day 21 clinic visit. VAX2012Q was generally well tolerated, with mild to moderate arm pain the most commonly reported adverse event. Complete study results will be submitted for future publication.

read more

VaxInnate Updates Plans to Advance Lead Vaccine Candidate, VAX2012Q in Elderly

VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, provided an update on clinical development plans for the Company’s experimental recombinant quadrivalent vaccine, VAX2012Q. VaxInnate plans to advance VAX2012Q into a Phase 1b/2 study for the prevention of seasonal influenza in elderly individuals by the end of 2014.

read more

VaxInnate Receives $2.1 million from New Jersey’s Technology Business Tax Certificate Transfer Program

VaxInnate Corporation, a biotechnology firm pioneering a breakthrough technology platform for the development of novel vaccines, announced today that it has received $2.1 million in non-dilutive financing through New Jersey’s Technology Business Tax Certificate Transfer (NOL) Program. This is the fifth year that VaxInnate has been selected to participate in the program, a state initiative designed to spur innovation and job creation by assisting promising early-stage biotechnology, life sciences and technology firms.

read more

VaxInnate Awarded U.S. Government Grant to Develop Dengue Vaccine

Mosquito-borne disease identified as emerging public health threat for Americans. VaxInnate Corporation announced today that it has been awarded a grant by the National Institute of Allergy and Infectious Diseases (NIAID) to fund the development of a recombinant vaccine for the prevention of dengue, a disease that kills an estimated 25,000 people annually. VaxInnate is a biotechnology firm pioneering breakthrough technology for developing novel vaccines.

read more

Two New Executives Join VaxInnate Management Team

VaxInnate Corporation today announced the expansion of its executive management team with the addition of Christine Mayer as Vice President of Business Development and Katalin Abraham as Vice President of Regulatory Affairs. VaxInnate is a biotechnology firm pioneering breakthrough technology for the development of novel vaccines.

read more

Lt. Governor Kim Guadagno Visits VaxInnate

Lt. Governor Kim Guadagno visited the headquarters of VaxInnate Corporation today, where she continued her statewide tour to support the expansion of New Jersey’s life sciences companies and lauded the biotechnology company for its commitment to the state and efforts to develop novel vaccines.

read more

VaxInnate Names Wayne Pisano as its New CEO

Former CEO of Sanofi Pasteur brings 30 years of pharmaceutical and vaccine leadership to NJ biotech firm. VaxInnate Corporation today announced that Wayne Pisano has joined the Company as President and Chief Executive Officer (CEO), and become a member of the Board. Pisano was formerly the President and CEO of sanofi pasteur, a division of sanofi-aventis Group and the world’s largest vaccine business.

read more

VaxInnate Awarded Contract by the U.S. Government To Develop Recombinant Seasonal and Pandemic Flu Vaccines

VaxInnate Corporation today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines. VaxInnate is a biotechnology firm pioneering breakthrough technology for use in developing novel vaccines. The contract initially provides funding of $118 million for a base period of 36 months, with an option to extend for 24 months. The contract is effective on February 24, 2011.

read more